𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Scribed by Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin

Book ID
117298998
Publisher
The Lancet
Year
2006
Tongue
English
Weight
134 KB
Volume
367
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sustained efficacy up to 4·5 years of a
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

## Background: Effective vaccination against hpv 16 and hpv 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent hpv-16/18 l1 virus-like part